In the historic period, the growth can be attributed to the increasing prevalence of chronic diseases, heightening demand for targeted therapies, advancements in drug delivery systems and enhanced ...

So, what were the major themes to come out of BIO Boston 2025? Who’s getting excited about what? And – besides the obvious ...

The companies place the partnership’s value at up to $1.5 billion, including an undisclosed up-front payment in the ...

Argenx wants to get in on the macrocyclic peptide action, penning a deal worth $1.5 billion in biobucks with Californian ...

Macrocyclic peptides are designed to engage complex targets like biologics but pass through cell membranes like small ...

The partners will use UNP's AI-based macrocycle discovery platform to develop synthetic peptide therapeutics for multiple disease targets.

B7-33 is a synthetic peptide derived from the relaxin protein family, specifically designed to interact with the relaxin ...

GLP-1 drugs currently being tested in China target complications associated with obesity such as heart disease, fatty liver ...

UNP to receive a double digit million dollar upfront payment, near-term payments and up to approximately $1.5B in potential milestone payments plus ...

Acute flares in patients with RA were linked to higher risk for AD/ADRD, but the relationship was not significant.

Dr. Kimberly Trotter distilled four high-impact disease clusters—gout, rheumatoid arthritis (RA), systemic lupus ...

The story of the “Pharaoh’s Curse” haunted archaeologists for hundreds of years. It started with the excavation of King ...